Immune suppression and evasion in patients with head and neck cancer (Q58289735)

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immunotherapy of cancer in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Regulatory T cells and IL-10 in allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

T regulatory cells and allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Regulatory T cells and mechanisms of immune system control

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Naturally occurring regulatory T cells: recent insights in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Myeloid derived suppressor cells and their role in tolerance induction in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Myeloid-derived suppressor cell heterogeneity and subset definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Macrophage polarization in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Monocyte and macrophage heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immunohistochemical localization of interleukin-10 in human oral and pharyngeal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immunomodulatory effects of anti-angiogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Galectins as modulators of tumor progression in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Expression of galectins in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Soluble HLA-G: Are they clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Identification and expansion of human colon-cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

CD133, one of the markers of cancer stem cells in Hep-2 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Modulation of T-cell activation by malignant melanoma initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Glioma-associated cancer-initiating cells induce immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Immunoregulatory properties of CD44+ cancer stem‐like cells in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FACMO.V1I0.21809